在经过心脏移植后不久出现t(3;3)(q21.3;q26.2)急性髓细胞白血病个案中，由阿扎胞苷和维诺托拉克斯成功实现异基因造血干细胞移植的桥接。
Successful Bridging to Allogeneic Hematopoietic Stem Cell Transplantation by Azacitidine and Venetoclax in a Case of Acute Myeloid Leukemia With t(3;3)(q21.3;q26.2) Developed Early After Orthotopic Heart Transplantation.
发表日期：2023 Apr 02
作者：
Tomoaki Ueda, Jiro Fujita, Yasuhiro Akazawa, Ai Kawamura, Takahiro Matsui, Akihisa Hino, Shinsuke Kusakabe, Takao Sudo, Kentaro Fukushima, Takafumi Yokota, Shigeru Miyagawa, Yasushi Sakata, Naoki Hosen
来源：
Stem Cell Research & Therapy
摘要：
一名48岁男性患者在接受心脏肉芽肿的无配型的脑死亡供体移植手术8个月后，发展为带有t(3;3)(q21.3;q26.2)染色体突变的急性髓性白血病 (AML)。诊断AML时，他已有中风和慢性肾功能衰竭的后遗症。他接受了3个周期的阿扎胞苷和维尼托克拉克斯诱导治疗，完全达到血液学缓解，但计数恢复不完整，没有引起严重并发症，包括感染。他接着接受了与 HLA-8/8匹配，ABO血型匹配的无关女性供体的异基因外周血干细胞移植，成功实现供体细胞移植。移植的心脏仍然正常运作，冠状动脉未受到损伤，即使在异基因外周血干细胞移植后仍然如此。虽然AML随后复发，但阿扎胞苷/维尼托克拉克斯即使在心脏移植后早期发病的情况下，仍是一种可承受的桥梁治疗。版权所有©2023 Elsevier Inc.。保留所有权利。
A 48-year-old male patient developed acute myeloid leukemia (AML) with t(3;3)(q21.3;q26.2) chromosomal mutation 8 months after orthotopic heart transplantation from a human leukocyte antigen-unmatched brain-dead donor for cardiac sarcoidosis. He had sequelae of stroke and chronic renal failure at the time of AML diagnosis. He received 3 cycles of azacitidine and venetoclax induction therapy and achieved complete hematological remission with incomplete count recovery without causing severe complications, including infection. He sequentially underwent allogeneic peripheral blood stem cell transplantation from a HLA-8/8 matched, ABO-blood matched, unrelated female donor and successfully achieved donor cell engraftment. His transplanted heart was viable, and the coronary vessels were not damaged even after allogeneic peripheral blood stem cell transplantation. Although AML relapsed afterward, azacytidine/venetoclax was a tolerable bridging therapy even for early-onset AML after heart transplantation.Copyright © 2023 Elsevier Inc. All rights reserved.